{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:22:35Z","timestamp":1782354155065,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.nefroe.2022.11.014","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T10:31:09Z","timestamp":1669372269000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet"],"prefix":"10.1016","volume":"43","author":[{"given":"Luciano Artur Lopes","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Augusto Gon\u00e7alves","family":"Amoedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa de Sousa Costa Pinto Ferreira","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Alexandre Mateus Prazeres","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Miguel Machado D\u00f3ria","family":"Fraz\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Luiz Loureiro","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2022.11.014_bib0110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/BJ20121284","article-title":"Wnt\/beta-catenin signalling: from plasma membrane to nucleus","volume":"450","author":"Kim","year":"2013","journal-title":"Biochem J"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cca.2019.12.008","article-title":"Sclerostin within the chronic kidney disease spectrum","volume":"502","author":"Bouquegneau","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0140","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/0886022X.2016.1160207","article-title":"Sclerostin levels in uremic patients: a link between bone and vascular disease","volume":"38","author":"Bruzzese","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2369-15-190","article-title":"Serum sclerostin is an independent predictor of mortality in hemodialysis patients","volume":"15","author":"Gon\u00e7alves","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ndt\/gfu301","article-title":"High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study","volume":"30","author":"Drechsler","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ckj\/sfz034","article-title":"Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis","volume":"13","author":"Wolf","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0160","article-title":"Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics","author":"Arenas","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000496562","article-title":"Improved control of secondary hyperparathyroidism in hemodialysis patients switching from oral cinacalcet to intravenous etelcalcetide especially in nonadherent patients","volume":"48","author":"Xipell","year":"2019","journal-title":"Blood Purif"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0175","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.kint.2017.12.014","article-title":"Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial","volume":"93","author":"Floege","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0185","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","article-title":"Effects of PTH on osteocyte function","volume":"54","author":"Bellido","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0190","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/jbmr.520","article-title":"Osteoblast extracellular Ca2+-sensing receptor regulates bone development, mineralization, and turnover","volume":"26","author":"Dvorak-Ewell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0195","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12882-016-0392-6","article-title":"Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism","volume":"17","author":"Kuczera","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11255-018-2050-3","article-title":"Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients","volume":"51","author":"Pietrzyk","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cca.2020.05.023","article-title":"The bone-vessel axis in chronic kidney disease: an update on biochemical players and its future role in laboratory medicine","volume":"508","author":"Pereira","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nefroe.2022.11.014_bib0210","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422001390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422001390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:50:42Z","timestamp":1761853842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251422001390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2013251422001390"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.11.014","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}